Trinity Biotech (TRIB) Liabilities and Shareholders Equity (2009 - 2025)

Trinity Biotech has disclosed Liabilities and Shareholders Equity across 17 years of filings, most recently posting $105.2 million for Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $105.2 million, up 1.82% year-over-year; the trailing twelve-month figure through Dec 2025 was $405.5 million (up 5.22% YoY), and the FY2025 annual result was $105.2 million, up 1.82% from the prior year.
• Liabilities and Shareholders Equity came in at $105.2 million for Q4 2025 at Trinity Biotech, up from $99.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $136.0 million in Q1 2021 to a low of $59.4 million in Q4 2023.
• The 5-year median for Liabilities and Shareholders Equity is $98.8 million (2022), against an average of $99.0 million.
• Across the five-year window, Liabilities and Shareholders Equity plunged 35.47% in 2023 and soared 73.79% in 2024, its largest moves.
• Trinity Biotech's Liabilities and Shareholders Equity stood at $118.9 million in 2021, then fell by 22.53% to $92.1 million in 2022, then tumbled by 35.47% to $59.4 million in 2023, then jumped by 73.79% to $103.3 million in 2024, then climbed by 1.82% to $105.2 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $105.2 million (Q4 2025), $99.6 million (Q2 2025), and $103.3 million (Q4 2024), per Business Quant data.